Onconetix, Inc. Financing Cash Flow
Onconetix, Inc. (ONCO) reported Financing Cash Flow of $4.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Onconetix, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $4.17M, a 459.83% increase year-over-year.
- Onconetix, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $631.79K, a 77.99% decline year-over-year.
- Onconetix, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $6.55M, a 402.51% increase year-over-year.
- Onconetix, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $4.29M, a 641.59% increase year-over-year.
- Onconetix, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $14.45M, a 114.33% increase from fiscal 2024.
- Onconetix, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $6.74M, a 551.47% increase from fiscal 2023.
- Onconetix, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.04M, a 96.82% decline from fiscal 2022.
- Onconetix, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $32.53M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.80M 10-Q · filed 2026-08-13 | $11.35M derived: sum of 3 quarters · filed 2026-08-13 | $15.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $631.79K 10-Q · filed 2026-05-13 | $7.18M derived: sum of 2 quarters · filed 2026-05-13 | $11.47M derived: sum of 3 quarters · filed 2026-05-13 | $12.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $10.84M derived: sum of 2 quarters · filed 2026-03-13 | $11.58M derived: sum of 3 quarters · filed 2026-08-13 | $14.45M 10-K · filed 2026-03-13 |
| 2025-09-30 | $4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.04M derived: sum of 2 quarters · filed 2026-08-13 | $7.91M 10-Q · filed 2025-11-13 | $9.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $744.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.61M 10-Q · filed 2026-08-13 | $4.92M derived: sum of 3 quarters · filed 2026-08-13 | $5.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.87M 10-Q · filed 2026-05-13 | $4.17M derived: sum of 2 quarters · filed 2026-05-13 | $4.75M derived: sum of 3 quarters · filed 2026-05-13 | $4.41M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.88M derived: sum of 2 quarters · filed 2026-03-13 | $1.54M derived: sum of 3 quarters · filed 2026-03-13 | $6.74M 10-K · filed 2026-03-13 |
| 2024-09-30 | $578.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $235.22K derived: sum of 2 quarters · filed 2025-11-13 | $5.44M 10-Q · filed 2025-11-13 | $5.44M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$343.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $4.86M 10-Q · filed 2025-08-14 | $4.86M derived: sum of 3 quarters · filed 2025-08-14 | $6.16M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.21M 10-Q · filed 2025-06-12 | $5.21M derived: sum of 2 quarters · filed 2025-06-12 | $6.50M derived: sum of 3 quarters · filed 2025-06-12 | $6.29M derived: sum of 4 quarters · filed 2025-06-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $1.30M derived: sum of 2 quarters · filed 2025-06-02 | $1.08M derived: sum of 3 quarters · filed 2025-06-02 | $1.04M 10-K · filed 2025-06-02 |
| 2023-09-30 | $1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-10 | $1.08M derived: sum of 2 quarters · filed 2024-12-10 | $1.04M 10-Q · filed 2024-12-10 | $452.22K derived: sum of 4 quarters · filed 2024-12-10 |
| 2023-06-30 | -$214.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-29 | -$263.62K 10-Q · filed 2024-08-29 | -$846.45K derived: sum of 3 quarters · filed 2024-08-29 | $7.88M derived: sum of 4 quarters · filed 2024-08-29 |
| 2023-03-31 | -$48.95K 10-Q · filed 2024-05-20 | -$631.79K derived: sum of 2 quarters · filed 2024-05-20 | $8.09M derived: sum of 3 quarters · filed 2024-05-20 | $14.91M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | -$582.84K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $8.14M derived: sum of 2 quarters · filed 2024-04-11 | $14.96M derived: sum of 3 quarters · filed 2024-04-11 | $32.53M 10-K · filed 2024-04-11 |
| 2022-09-30 | $8.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | $15.54M derived: sum of 2 quarters · filed 2023-11-17 | $33.12M 10-Q · filed 2023-11-17 | $32.98M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | $6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-10-20 | $24.39M 10-Q · filed 2023-10-20 | $24.25M derived: sum of 3 quarters · filed 2023-10-20 | |
| 2022-03-31 | $17.57M 10-Q · filed 2023-05-12 | $17.43M derived: sum of 2 quarters · filed 2023-05-12 | ||
| 2021-12-31 | -$137.21K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$334.19K 10-K · filed 2023-03-09 | ||
| 2021-09-30 | -$196.97K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |